Wednesday, 19 September 2018

Admedus introduces heart tissue engineering technology in India

01 February 2018 | News

Regulatory approval to launch CardioCel, a bio-scaffold for the management of congenital and adult structural heart abnormalities, in India was granted in November 2017.

Image credit- popsci.com

Image credit- popsci.com

Admedus in partnership with Syncronei Medical India and supported by the Australian Trade and Investment Commission (Austrade) has now launched its clinically-superior Adapt technology in the country. Physicians in India now have access to the benefits of the disruptive Adapt technology and Admedus’ flagship product CardioCel to provide life-changing outcomes for patients.

To support the launch of CardioCel in India, Adapt inventor and Professor Leon Neethling, Vice President, Cardiovascular Technologies Admedus will deliver a comprehensive series of meetings and presentations with physicians in major health centres across India to demonstrate the product’s clinical applications and benefits.

Regulatory approval to launch CardioCel, a bio-scaffold for the management of congenital and adult structural heart abnormalities, in India was granted in November 2017. Primarily used in restorative structural heart repair and reconstruction, Adapt treated tissue provides unparalleled resistance to calcification. It delivers transformative repair with long-term durability that enables native cells to successfully grow and differentiate through the entire repair, without calcification or toxicity.

Both Admedus and Syncronei Medical are looking forward to working closely with Indian clinicians, health officials and key opinion leaders (KOLs) to build productive long-term relationships focused on helping to improve the health outcomes and quality of life for Indian patients with heart disease.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!




Survey Box

Are portable diagnostics taking healthcare into the household?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls